GlassScriptPhysician profile
Lewis Attas
NPI 1437102571
$5,505.15
in general payments reported to CMS, 2019-2025
51 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $159 · 2021: $493 · 2022: $737 · 2023: $1,010 · 2024: $1,717 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,484 · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,484.02 |
| Education | $329.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,308.31 | 2019-2025 | |
| Incyte Corporation | $375.03 | 2019-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $331.91 | 2019-2025 | Lynparza, Tagrisso, Enhertu |
| Alexion Pharmaceuticals, INC. | $322.22 | 2019-2025 | Soliris, Ultomiris |
| Amgen INC. | $306.88 | 2021-2024 | Lumakras |
| Merck Sharp & Dohme LLC | $261.76 | 2019-2024 | Keytruda, Reblozyl, Welireg |
| Genzyme Corporation | $260.83 | 2020-2025 | |
| Daiichi Sankyo INC. | $259.55 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Novocure Gmbh | $250.00 | 2022 | |
| Janssen Biotech, INC. | $145.52 | 2022-2025 | Rybrevant, Tecvayli, Darzalex |
| Pfizer INC. | $136.63 | 2020-2025 | |
| Celgene Corporation | $134.36 | 2019-2024 | Pomalyst, Reblozyl |
| Intuitive Surgical, INC. | $128.75 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.22 | 2020-2025 | Reblozyl, Opdivo |
| Blueprint Medicines Corporation | $88.68 | 2024 | Ayvakit |
Show all 49 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Attas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.